These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 20210915)
101. [Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes]. Valdés R E; Soto-Chacón E; Lahsen M R; Barrera H C; Candía P P Rev Med Chil; 2008 Jul; 136(7):915-20. PubMed ID: 18949170 [TBL] [Abstract][Full Text] [Related]
102. Newly approved and promising antidiabetic agents. Combettes M; Kargar C Therapie; 2007; 62(4):293-310. PubMed ID: 17983555 [TBL] [Abstract][Full Text] [Related]
103. [Approach to diabetic therapy. 2. Selection and the use of oral antidiabetics. 3) Biguanides and alpha-glucosidase inhibitors]. Onuma T Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1536-43. PubMed ID: 11062901 [No Abstract] [Full Text] [Related]
104. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Marchetti P; Navalesi R Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043 [TBL] [Abstract][Full Text] [Related]
105. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Marchetti P; Giannarelli R; di Carlo A; Navalesi R Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902 [TBL] [Abstract][Full Text] [Related]
107. Diabetes mellitus and kidney disease in the elderly. Iglesias P; Heras M; Díez JJ Nefrologia; 2014 May; 34(3):285-92. PubMed ID: 24798557 [TBL] [Abstract][Full Text] [Related]
108. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. Neumiller JJ; Alicic RZ; Tuttle KR J Am Soc Nephrol; 2017 Aug; 28(8):2263-2274. PubMed ID: 28465376 [TBL] [Abstract][Full Text] [Related]
109. Management of hyperglycemia in patients with chronic kidney disease. Aires Neto P; Gomes HV; Campos M J Nephrol; 2013; 26(4):629-35. PubMed ID: 23807643 [TBL] [Abstract][Full Text] [Related]
110. Management Strategies for Patients with Diabetic Kidney Disease and Chronic Kidney Disease in Diabetes. Yakush Williams JK Nurs Clin North Am; 2017 Dec; 52(4):575-587. PubMed ID: 29080579 [TBL] [Abstract][Full Text] [Related]
111. Variation of Pharmacokinetic Profiles of Some Antidiabetic Drugs from Nanostructured Formulations Administered Through Pulmonary Route. Mukherjee B; Paul P; Choudhury A; Bhattacharya S; Maji R; Dutta L Curr Drug Metab; 2016; 17(3):271-8. PubMed ID: 26467065 [TBL] [Abstract][Full Text] [Related]
112. Medication dosing in patients with chronic kidney disease. Zuber K; Liles AM; Davis J JAAPA; 2013 Oct; 26(10):19-25. PubMed ID: 24201917 [TBL] [Abstract][Full Text] [Related]
113. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Reilly JB; Berns JS Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915 [TBL] [Abstract][Full Text] [Related]
114. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting]. Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840 [TBL] [Abstract][Full Text] [Related]
115. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Snyder RW; Berns JS Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745 [TBL] [Abstract][Full Text] [Related]
116. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Tornio A; Niemi M; Neuvonen PJ; Backman JT Trends Pharmacol Sci; 2012 Jun; 33(6):312-22. PubMed ID: 22475684 [TBL] [Abstract][Full Text] [Related] [Previous] [New Search]